TickerTalks
Browse all tickers →
TickerTalks›$CAI
CACAI

Caris Life Sciences, Inc.

$CAI·$4.4B·Biotechnology·Healthcare
$16.37+0.3%YTD-40.6%1Y-44.7%
Mentions · last 7 days
2026-07-28: 2 posts2026-07-29: 4 posts2026-07-30: 17 posts2026-07-31: 5 posts2026-08-01: 6 posts2026-08-02: 5 posts2026-08-03: 8 posts47+19%
Price updated 2m ago·X counts updated 19h ago
CACAI
$CAICaris Life Sciences, Inc.
$16.37+0.31%47 posts+19%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $CAI, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-08-01

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Caris Life Sciences launched Caris Detect — cancer early-detection blood test, $1B revenue guidance, Aug 5 print.

Caris Life Sciences is a molecular diagnostics company focused on precision oncology — tumor profiling for therapy selection plus the newly-launched Caris Detect multi-cancer early-detection blood test. Down 40% YTD as the newly-listed biotech ADR faced growth-story compression, but the Caris Detect launch resets the equity story into the August 5 print.

Where the setup sits:

  • Q1 was a genuine beat: EPS negative $0.0018 vs negative $0.02 consensus with revenue $220M (+79% YoY) — the operational execution is materially better than sell-side expected.
  • The Caris Detect launch is the substantive event: the world's most sensitive multi-cancer early detection blood test — this is a major product launch that opens a new market vector beyond therapy selection.
  • The $1B revenue guidance and $100M share repurchase is aggressive: 23% YoY growth guidance plus buyback capacity is what supports the equity thesis at the current $4.4B market cap.
  • Position at 5% of 52-week range and 28% below the 200-day MA — the tape is deeply discounted, and the setup has real upside if the print delivers.

August 5 is the pivot: continued Caris Detect commercial ramp plus firm 2027 revenue guidance is what breaks the 5%-of-52w capitulation; a soft launch print or a fresh competitive setback from Grail or Exact Sciences and the -40% YTD extends toward fresh lows.

Agrees with X sentimentX captures the substance — the Caris Detect launch as the world's most sensitive multi-cancer early detection blood test, $1B revenue guidance with 23% YoY growth, and $100M share repurchase program are all real; the aggressive-long-positioning tone tracks the precision-oncology catalyst.

What to watch: The August 5 Q2 print — continued Caris Detect commercial ramp plus firm 2027 revenue guidance breaks the 5%-of-52w capitulation; a soft launch print or competitive setback from Grail/Exact Sciences and the -40% YTD extends.

On the calendar: 2026-08-05 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment6 posts analyzed · as of 2026-07-03

Caris Life Sciences (CAI) launched Caris Detect, the world's most sensitive multi-cancer early detection blood test. Guided $1B in revenue with 23% YoY growth and $100M share repurchase program. The tone is aggressive long positioning into the precision-oncology catalyst.

Read the AI verdict + X sentiment for $CAI

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Precision oncology TechBio company using AI on comprehensive molecular tumor profiles to guide cancer treatment decisions.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $CAI.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $CAI

Partial — Precision oncology TechBio company using AI on comprehensive molecular tumor profiles to guide cancer treatment decisions; partial earnings exposure to biotechnology demand dynamics through its product portfolio.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.0%YTD
+37.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-11.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
14.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
15.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
2.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
6.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
68.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.00$-0.02+91.0%
Q4 2025Feb 26, 2026$0.28$0.01+2700.0%
Q3 2025Nov 5, 2025$0.08$-0.08+200.0%
Q2 2025Aug 12, 2025$-0.54$-0.21-157.1%
Next earningsWed, Aug 5·consensus EPS $0.01

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$216.2M+78.8%65.4%2.4%$-0.00$22.5M
Q4 FY25$292.9M+192.7%75.4%30.2%$0.29$39.7M
Q3 FY25$216.8M+168.8%68.0%15.1%$0.09$55.3M
Q2 FY25$181.4M+79.9%62.7%9.9%$-1.93$5.9M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.0B$985.3M – $1.0B$0.13$0.12 – $0.139
FY27$1.2B$1.1B – $1.2B$0.35$0.20 – $0.459
FY28$1.4B$1.2B – $1.5B$0.55$0.43 – $0.788
FY29$1.6B$1.5B – $1.7B$0.78$0.72 – $0.817
FY30$1.8B$1.7B – $1.9B$1.04$0.96 – $1.087

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.8%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-3.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-24.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 11.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today43.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.595-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyMay 15Jon HalbertDirector68.0K sh$990KBuyMay 11Jeff L VacircaDirector31.1K sh$501K
+ 18 other (13 awards · 5 inkinds) in window

See when $CAI insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 58-K — Item 5.07: Shareholder vote
AI summary

Caris Life Sciences, Inc. (CAI) held its 2026 Annual Meeting of Shareholders on June 4, 2026, with 273,714,520 of 282,662,545 eligible shares represented (96.8% quorum). Shareholders voted on two proposals: (1) election of ten director nominees to serve until the 2027 Annual Meeting, and (2) ratification of Deloitte & Touche LLP as auditor for fiscal year 2026. All ten directors were elected, though Peter Castleman drew notably higher withhold votes (~62M) compared to peers (~34–48M); Deloitte ratification vote totals were cut off in the excerpt but both proposals passed. This is a routine annual governance filing with no strategic or financial significance.

8-KAgreement terminatedApr 28-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated · Item 2.03: Material debt obligation
8-KPress release / Reg FDFeb 268-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
+ 13 other (5 13Gs · 2 proxys · 1 CERT · 1 8-A12B) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Caris Life Sciences: Disrupting Cancer Screening And Therapy Selectionseekingalpha.com·14d agoCaris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026prnewswire.com·19d agoCaris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testingprnewswire.com·21d agoCaris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood Testprnewswire.com·34d agoVirginia Information Technologies Agency Selects CAI to Deliver Statewide Cybersecurity Services to Local Governmentsglobenewswire.com·41d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$REPL$CAPR$IBRX$REGN$HALO$AURA$ALLO$MRNA
Voices on X · last 7 days

No standout posts about $CAI on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport